Glypharma Overview

  • Founded
  • 2012
  • Status
  • Acquired/​Merged
  • Employees
  • 3
  • Latest Deal Type
  • M&A

Glypharma General Information


Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The company's therapies include a novel proprietary Glucagon-Like Peptide-2 (GLP-2) analogue, enabling patients to get hematological malignancies for myelotoxic therapies.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Parent Company
Primary Office
  • 1188 Union
  • Suite 504
  • Montreal, Quebec H3B 0E5
  • Canada
+1 (514) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Glypharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Oct-2018 0000 Completed Pre-Clinical Trials
1. Early Stage VC 05-Oct-2012 0000 0000 Completed Pre-Clinical Trials
To view Glypharma’s complete valuation and funding history, request access »

Glypharma Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The co
Montreal, Canada
3 As of 2016
000000&0 0000

0000 000

met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Santa Monica, CA
000 As of 0000
000 0000-00-00
000000&0 00000


nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
Thousand Oaks, CA
00000 As of 0000
000000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glypharma Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000000 00000000 Venture Capital-Backed San Carlos, CA 000.00 0000000000 0 000.00
0000000000 Venture Capital-Backed Gaithersburg, MD 00 00000 00000000000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
You’re viewing 5 of 26 competitors. Get the full list »

Glypharma Executive Team (2)

Name Title Board Seat Contact Info
Jean-Francois Leprince Interim Chief Executive Officer & Board Member
Micheline Beauvais Director, Finance
To view Glypharma’s complete executive team members history, request access »

Glypharma Board Members (6)

Name Representing Role Since
Gaétan Gravel Self Board Member 000 0000
Jean-Francois Leprince Self Interim Chief Executive Officer & Board Member 000 0000
Michael Seckler Self Board Member 000 0000
Pierre Lapalme Self Chairman 000 0000
Thomas Schuetz Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Glypharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glypharma Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CTI Life Sciences Fund Venture Capital Minority 000 0000 000000 0
Ferring International Center Corporation Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
To view Glypharma’s complete investors history, request access »